CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Remicadebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00778869
NCT00778869Phase 4Completed
CompareCT.gov

Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls

Merck Sharp & Dohme LLC·interventional·Posted Oct 24, 2008·Updated Jul 3, 2015

In Brief

A Phase 4 clinical trial evaluating Remicade for Spondylitis, Ankylosing. Completed, enrolled 10 participants.

Detailed Summary

This is an open-label, controlled sub-study to the parent protocol (P04041, NCT00779935) to examine the expression profile of genes in patients in the active stage of ankylosing spondylitis (AS) compared to the healthy population as control, moreover to examine the changes in expression profile during anti-tumor necrosis factor (TNF)-alpha treatment (Remicade).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylitis, Ankylosing
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 24, 2008
Enrollment StartAug 1, 2005
Primary CompletionAug 1, 2005
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 17.7 years ago

Interventions

Remicadebiological

Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.